Effect of Antiandrogen Treatment on Bone Density and Bone Geometry in Adolescents with Polycystic Ovary Syndrome

Journal of Pediatric and Adolescent Gynecology

Volumn 25, Issue 3, 2012, Pages 175-180

  Bechtold, Susanne ^a   Dalla Pozza, Robert ^a   Putzker, Stephanie ^a   Roeb, Julia ^a   Buckel, Matthias ^a   Weissenbacher, Claudia ^a   Schmidt, Heinrich ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Antiandrogen; Bone geometry; Bone mineralization; Peripheral quantitative computed tomography; Polycystic ovary syndrome

Indexed keywords

FLUTAMIDE; METFORMIN; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADOLESCENT DISEASE; ANTIANDROGEN THERAPY; ARTICLE; BONE DENSITY; BONE STRENGTH; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CORTICAL BONE; FEMALE; GRIP STRENGTH; HUMAN; MUSCLE MASS; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRABECULAR BONE; TREATMENT DURATION;

ADOLESCENT; ANDROGEN ANTAGONISTS; BONE DENSITY; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; FOREARM; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MUSCLE STRENGTH; MUSCLE, SKELETAL; POLYCYSTIC OVARY SYNDROME; RADIUS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84860838359     PISSN: 10833188     EISSN: 18734332     Source Type: Journal    
DOI: 10.1016/j.jpag.2011.11.010     Document Type: Article

References (33)

1. Azziz R., Sanchez L.A., Knochenhauer E.S., et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004, 89:453.
2. Bronstein J., Tawdekar S., Liu Y., et al. Age of onset of polycystic ovarian syndrome in girls may be earlier than previously thought. J Pediatr Adolesc Gynecol 2011, 24:15.
3. Diamanti-Kandarakis E. PCOS in adolescents. Best Pract Res Clin Obstet Gynaecol 2010, 24:173.
4. Ibáñez L., de Zegher F. Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy. J Clin Endocrinol Metab 2005, 90:39.
5. Ehrmann D.A. Polycystic ovary syndrome. N Engl J Med 2005, 352:1223.
6. To W.W., Wong M.W. A comparison of bone mineral density in oligomenorrhoeic adolescents with polycystic ovaries and normal ovaries. Gynecol Endocrinol 2005, 20:237.
7. Kassanos D., Trakakis E., Baltas C.S., et al. Augmentation of cortical bone mineral density in women with polycystic ovary syndrome: a peripheral quantitative computed tomography (pQCT) study. Hum Reprod 2010, 25:2107.
8. Dixon J.E., Rodin A., Murby B., et al. Bone mass in hirsute women with androgen excess. Clin Endocrinol (Oxf) 1989, 30:271.
9. Di Carlo C., Shoham Z., MacDougall J., et al. Polycystic ovaries as a relative protective factor for bone mineral loss in young women with amenorrhea. Fertil Steril 1992, 57:314.
10. Zborowski J.V., Cauley J.A., Talbott E.O., et al. Clinical Review 116: Bone mineral density, androgens, and the polycystic ovary: the complex and controversial issue of androgenic influence in female bone. J Clin Endocrinol Metab 2000, 85:3496.
11. Yuksel O., Dokmetas H.S., Topcu S., et al. Relationship between bone mineral density and insulin resistance in polycystic ovary syndrome. J Bone Miner Metab 2001, 19:257.
12. Ibáñez L., Lopez-Bermejo A., Diaz M., et al. Low-dose pioglitazone, flutamide, metformin plus an estro-progestagen for non-obese young women with polycystic ovary syndrome: increasing efficacy and persistent safety over 30 months. Gynecol Endocrinol 2010, 26:869.
13. Bonjour J.P., Theintz G., Law F., et al. Peak bone mass. Osteoporos Int 1994, 4(Suppl 1):7.
14. Ibáñez L., Diaz M., Sebastiani G., et al. Treatment of androgen excess in adolescent girls: ethinylestradiol-cyproteroneacetate versus low-dose pioglitazone-flutamide-metformin. J Clin Endocrinol Metab 2011, 96:3361.
15. Matsuda M., DeFronzo R.A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999, 22:1462.
16. Ibáñez L., de Zegher F. Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome. Hum Reprod 2003, 18:57.
17. Brandt I., Reinken L. [The growth rate of healthy children in the first 16 years: Bonn-Dortmund longitudinal developmental study]. Klin Padiatr 1988, 200:451.
18. Molarius A., Seidell J.C., Sans S., et al. Waist and hip circumferences, and waist-hip ratio in 19 populations of the WHO MONICA Project. Int J Obes Relat Metab Disord 1999, 23:116.
19. Tanner M. Growth at adolescence 1962, Oxford, Blackwell. 2nd ed.
20. Neu C.M., Manz F., Rauch F., et al. Bone densities and bone size at the distal radius in healthy children and adolescents: a study using peripheral quantitative computed tomography. Bone 2001, 28:227.
21. Neu C.M., Rauch F., Rittweger J., et al. Influence of puberty on muscle development at the forearm. Am J Physiol Endocrinol Metab 2002, 283:E103.
22. Rauch F., Neu C.M., Wassmer G., et al. Muscle analysis by measurement of maximal isometric grip force: new reference data and clinical applications in pediatrics. Pediatr Res 2002, 51:505.
23. Schoenau E., Neu C.M., Rauch F., et al. The development of bone strength at the proximal radius during childhood and adolescence. J Clin Endocrinol Metab 2001, 86:613.
24. Notelovitz M. Androgen effects on bone and muscle. Fertil Steril 2002, 77(Suppl 4):S34.
25. Dhuper S., Warren M.P., Brooks-Gunn J., et al. Effects of hormonal status on bone density in adolescent girls. J Clin Endocrinol Metab 1990, 71:1083.
26. Celotti F., Negri Cesi P. Anabolic steroids: a review of their effects on the muscles, of their possible mechanisms of action and of their use in athletics. J Steroid Biochem Mol Biol 1992, 43:469.
27. Bertelloni S., Baroncelli G.I., Federico G., et al. Altered bone mineral density in patients with complete androgen insensitivity syndrome. Horm Res 1998, 50:309.
28. Feldmann S., Minne H.W., Parvizi S., et al. Antiestrogen and antiandrogen administration reduce bone mass in the rat. Bone Miner 1989, 7:245.
29. Bertelloni S., Baroncelli G.I., Sorrentino M.C., et al. Androgen-receptor blockade does not impair bone mineral density in adolescent females. Calcif Tissue Int 1997, 61:1.
30. Lundon K.M., Jayo M.J., Register T.C., et al. The effect of androstenedione/estrone supplementation on cortical and cancellous bone in the young intact female monkey: a model for the effects of polycystic ovarian disease on the skeleton?. Osteoporos Int 2000, 11:778.
31. Steinberg K.K., Freni-Titulaer L.W., DePuey E.G., et al. Sex steroids and bone density in premenopausal and perimenopausal women. J Clin Endocrinol Metab 1989, 69:533.
32. Ibañez L., de Zegher F. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. Hum Reprod Update 2006, 12:243.
33. Frost H.M. Muscle, bone, and the Utah paradigm: a 1999 overview. Med Sci Sports Exerc 2000, 32:911.